Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB004 in EphA3-Expressing Hematologic Malignancies
NCT01211691Phase 2Suspended
- Sponsor
- Humanigen
- Start
- Sep 2010
- Primary completion
- Jul 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ifabotuzumab in hematologic malignancy, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelofibrosis (MF), sponsored by Humanigen. Started Sep 2010; status: suspended.
02
Drugs
ifabotuzumab
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01211691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01211691.